Compare BGSF & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | SER |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0M | 56.4M |
| IPO Year | 2013 | 2024 |
| Metric | BGSF | SER |
|---|---|---|
| Price | $5.17 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 6.5K | ★ 51.7K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 36.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $93,310,000.00 | $130,000.00 |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.14 |
| 52 Week Low | $3.26 | $1.22 |
| 52 Week High | $7.83 | $5.83 |
| Indicator | BGSF | SER |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 42.92 |
| Support Level | $4.99 | $1.69 |
| Resistance Level | $5.79 | $2.29 |
| Average True Range (ATR) | 0.18 | 0.22 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 0.00 | 17.91 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.